Henrik Wulff, the man in charge of product supply at Novo Nordisk, just spent $11 billion ... Two of the new facilities, he said, one in Bloomington, Indiana, and one in Anagni, Italy, are extreme ...

The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will change hands “as soon as possible after the merger,” said Novo Nordisk, which has pledged to ...

These plants are located in diverse geographical locations: Agnani (Italy), Brussels (Belgium) and Bloomington (United States). Through this acquisition, Novo Nordisk aims to meet global demand ...

The letter indicates that Novo Nordisk already has 55% of the market ... sites covered by the deal is located in the US – at Bloomington, Indiana – while the other two are at Anagni in Italy ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.